10-Q: Nomad Power Solutions Completes Merger, Rebrands

Nomad Power Solutions, Inc. (formerly Lixte Biotechnology Holdings, Inc.) reported its Q2 2026 results, highlighting a strategic shift into AI energy infrastructure and the completion of its merger with NOMAD Transportable Power Systems, Inc.

Summary

• Nomad Power Solutions, Inc. (formerly Lixte Biotechnology Holdings, Inc.) filed its Q2 2026 Form 10-Q, detailing financial results and significant corporate changes.
• The company announced a strategic transformation to expand into AI energy infrastructure equipment and services, culminating in the acquisition of NOMAD Transportable Power Systems, Inc. on July 1, 2026.
• Following the acquisition, the company was renamed Nomad Power Solutions, Inc. and began trading under the new ticker symbol NMAD on Nasdaq.
• For the six months ended June 30, 2026, the company reported a net loss of $4,331,947 and used $3,468,083 in operating cash flow.
• As of June 30, 2026, the company had $12,670,143 in cash, but management concluded there is substantial doubt about its ability to continue as a going concern.
• The company has not generated revenue and relies on external financing to fund its operations and development programs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant net loss, ongoing cash burn, and substantial doubt about the company's ability to continue as a going concern, despite the strategic acquisition and rebranding.

Positives

• Successful completion of the merger with NOMAD Transportable Power Systems, Inc., diversifying the company's business into AI energy infrastructure.
• Completion of a registered direct offering on June 4, 2026, raising approximately $16.6 million in gross proceeds.
• Regained compliance with Nasdaq's minimum stockholders equity requirement on July 15, 2025, after a period of monitoring.
• The company's cash balance of $12,670,143 as of June 30, 2026, provides some short-term liquidity.

Negatives

• Incurred a net loss of $4,331,947 for the six months ended June 30, 2026, and $2,344,339 for the three months ended June 30, 2026.
• Used $3,468,083 in operating cash flow for the six months ended June 30, 2026, indicating ongoing cash burn.
• Substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months.
• The company has not generated any revenue since inception and does not expect to generate sustainable operating revenue for several years.
• The clinical trial for LB-100 in combination with atezolizumab is on an enrollment hold due to serious adverse events, potentially delaying development.
• Significant increase in general and administrative costs, up 196% for the six months ended June 30, 2026, compared to the prior year period.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company requires additional capital to fund its operations and development programs, and there is no assurance that such funding will be available.
• Serious adverse events in clinical trials could lead to trial holds, delays, increased costs, and potential termination of development programs.
• The integration of NOMAD Transportable Power Systems, Inc. and the transition to a new business model present execution risks.
• The company's biopharmaceutical and proton-therapy operations are subject to significant risks and uncertainties inherent in drug development.
• Geopolitical risks, inflation, interest-rate changes, and cybersecurity threats could adversely affect the company's operations and financial condition.

Future Outlook

The company anticipates continued need for additional capital to fund its operations, including clinical development programs and recommissioning of the LiGHT system equipment. Management is actively pursuing financing alternatives. The company does not expect to generate sustainable operating revenue for several years, if ever.

Management Comments

• Management has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern for a period of at least 12 months beyond the date these condensed consolidated financial statements are issued.
• Management is actively evaluating and pursuing additional financing alternatives, including equity and debt financings and potential strategic transactions.
• If the Company is unable to obtain the necessary funding, it may be required to delay, scale back, or eliminate its clinical development programs; curtail expenditures related to the LiGHT system; or pursue strategic alternatives, including potential asset sales or the cessation of operations.

Industry Context

StockSavvy.ai notes that the company's strategic pivot from biopharmaceuticals and proton therapy to AI energy infrastructure reflects a broader trend of companies seeking diversification and new growth avenues, particularly in technology-driven sectors. The acquisition of NOMAD positions the company within the growing battery energy storage systems market.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material pending or threatened legal proceedings as of June 30, 2026.

Related Party Transactions

• Accounts payable and accrued expenses include amounts due to related parties ($29,258 as of June 30, 2026).
• Employment agreements with officers Geordan Pursglove (CEO) and Peter Stazzone (CFO) detailing salaries and terms.
• Compensation paid to former officers Robert N. Weingarten and Dr. Jan H.M. Schellens during the prior year period.
• Director compensation paid to non-officer directors.

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises and stock-based compensation; potential upside from successful integration of NOMAD and new business strategy.
• Creditors: The company's going concern status raises concerns about its ability to meet future obligations.
• Employees: Continued employment dependent on the company's ability to secure funding and execute its strategy.
• Suppliers: Potential impact on payment terms and continuity of business due to financial instability.

Next Steps

• Finalize acquisition accounting for the merger with NOMAD Transportable Power Systems, Inc.
• File an amendment to its Current Report on Form 8-K to include historical financial statements of NOMAD and pro forma financial information by September 11, 2026.
• Continue pursuing additional financing alternatives to address going concern issues.
• Seek stockholder approval for the issuance of shares underlying the Series D Convertible Preferred Stock and an amendment to the 2020 Stock Incentive Plan.
• Await completion of the Netherlands Cancer Institute Institutional Review Board's review regarding the enrollment hold on the LB-100 clinical trial.

Key Dates

Recommendation

The company has undergone a significant strategic transformation with the acquisition of NOMAD and rebranding to Nomad Power Solutions, Inc., entering the AI energy infrastructure market. While this diversification offers potential, the company's persistent net losses, substantial cash burn, and the explicit statement of substantial doubt regarding its ability to continue as a going concern present significant risks. The successful integration of the new business and the ability to secure future financing are critical. Given the uncertainty and the early stage of the new strategy, a 'hold' recommendation is appropriate, pending further clarity on financial stability and operational execution.

Keywords

Nomad Power Solutions, Lixte Biotechnology, Merger, Acquisition, Energy Infrastructure, Biopharmaceutical, Clinical Trials, Going Concern